Back to top

Image: Bigstock

Zacks.com featured highlights include: Regeneron, AT&T, AMETEK, Hershey Company and BGC

Read MoreHide Full Article

For Immediate Release

Chicago, IL – September 25, 2018 - Stocks in this week’s article are Regeneron Pharmaceuticals, Inc. (REGN - Free Report) , AT&T Inc. (T - Free Report) , AMETEK, Inc. (AME), The Hershey Company (HSY - Free Report) and BGC Partners, Inc.

5 Stocks with Robust Sales Growth Worth Adding to Your Portfolio

When it comes to choosing stocks, investors often pick complex investment strategies in a bid to book higher returns. But with ever changing market dynamics, this may not yield the desired results always. Therefore, using conventional strategies, based on key fundamentals, to choose stocks is a wise decision.

One such strategy is sales growth. Maintaining steady sales growth is the key to survival for any business. Sales growth as such remains a vital measure for any corporate house, as it is important to growth projections and strategic decision-making.

So, when companies incur losses for a temporary period, they are valued on the basis of revenues, as top-line growth (or decline) is usually an indicator of a company's future earnings performance. Also, in contrast to price to earnings and price to book value ratios, which can turn negative and cease to be relevant, price-to-sales (P/S) ratio is available even for companies that have hit choppy waters.

Additionally, profits and book value are largely influenced by several factors including accounting decisions tied with depreciation, significant charges and inventory. However, management has limited opportunities to manipulate sales, which further underscores the importance of P/S ratio.

Hence, P/S ratio can serve as a more reliable metric for stock valuation. Focusing solely on sales growth is, however, not enough. A consideration of a company's cash position along with its sales can be a more dependable strategy. Significant cash in hand and steady cash flow give a company more flexibility with respect to business decisions and investments.

For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/324428/5-stocks-with-robust-sales-growth-worth-adding-to-portfolio

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

About Screen of the Week

Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine.  But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.

Follow us on Twitter:  http://twitter.com/zacksresearch

Join us on Facebook:  http://www.facebook.com/ZacksInvestmentResearch

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Contact: Jim Giaquinto

Company: Zacks.com

Phone: 312-265-9268

Email: pr@zacks.com

Visit: www.Zacks.com

Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Regeneron Pharmaceuticals, Inc. (REGN) - free report >>

AT&T Inc. (T) - free report >>

Hershey Company (The) (HSY) - free report >>